Just published
CLEAR Outcomes trial: bempedoic acid
Ray KK, Nicholls SJ, Li N, et al.
Lancet Diabetes Endocrinol 2024;12(1):19-28.
Lowering cholesterol reduces CV risk. Statins are the first-line option, but they may increase HbA1c and new-onset diabetes. A new prespecified analysis of the CLEAR Outcomes trial looks at bempedoic acid – a new agent for high cholesterol.
Read now